D-Deprenyl
 | |
| Systematic (IUPAC) name | |
|---|---|
|
(2S)-N-methyl-1-phenyl-N-prop-2-ynyl-propan-2-amine | |
| Identifiers | |
| CAS Number |
4528-51-2  |
| PubChem | CID 199605 |
| ChemSpider |
172774  |
| Chemical data | |
| Formula | C13H17N |
| Molar mass | 187.29 g·mol−1 |
| |
| |
| (what is this?) (verify) | |
D-Deprenyl, also known as or dextro-N-propargyl-N-methylamphetamine, is an MAO-B inhibitor that metabolizes into D-amphetamine and D-methamphetamine and is therefore also a norepinephrine-dopamine releasing agent.[1][2][3][4][5] It is the opposite enantiomer of L-deprenyl (selegiline).
L-Deprenyl, also an MAO-B inhibitor, metabolizes to L-amphetamine and L-methamphetamine, which are both norepinephrine releasing agents. In contrast, D-deprenyl additionally has dopaminergic effects and has been found to be reinforcing in scientific research, whereas L-deprenyl is not known to have any appreciable psychological reinforcement.[6][7]
See also
References
- ↑ C Thiffault, R Quirion, J Poirier (October 1997). "The effect of l-deprenyl, d-deprenyl and MDL72974 on mitochondrial respiration: a possible mechanism leading to an adaptive increase in superoxide dismutase activity". Molecular Brain Research 49 (1–2): 127–136. doi:10.1016/S0169-328X(97)00135-6. PMID 9387872.
- ↑ Srinivasan ThyagaRajan, Kelley S. Madden, Gary W. Boehm, Suzanne Y. Stevens, David L. Felten, Denise L. Bellinger (January 2013). "l-Deprenyl Reverses Age-Associated Decline in Splenic Norepinephrine, Interleukin-2 and Interferon-γ Production in Old Female F344 Rats". Neuroimmunomodulation 20 (2): 72–78. doi:10.1159/00034504. PMID 23207416.
- ↑ Dhanasekharan Muralikrishnan, Supriti Samantaray, Kochupurackal P. Mohanakumar (October 2003). "D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity". Synapse 50 (1): 7–13. doi:10.1002/syn.10239. PMID 12872288.
- ↑ László Simon, Géza Szilágyi, Zoltán Bori, Péter Orbay, Zoltán Nagy (November 2001). "(−)-d-Deprenyl attenuates apoptosis in experimental brain ischaemia". European Journal of Pharmacology 430 (2–3): 235–241. doi:10.1016/S0014-2999(01)01375-9. PMID 11711036.
- ↑ S Yasar, C W Schindler, E B Thorndike, I Szelenyi,S R Goldberg (April 1993). "Evaluation of the stereoisomers of deprenyl for amphetamine-like discriminative stimulus effects in rats.". Journal of Pharmacology and Experimental Therapeutics 265 (1): 1–6. PMID 8473997.
- ↑ Yasar S; Gaál J; Panlilio LV; et al. (January 2006). "A comparison of drug-seeking behavior maintained by d-amphetamine, l-deprenyl (selegiline) and d-deprenyl under a second-order schedule in squirrel monkeys". Psychopharmacology 183 (4): 413–21. doi:10.1007/s00213-005-0200-7. PMC 1360227. PMID 16292593.
- ↑ Winger GD, Yasar S, Negus SS, Goldberg SR (December 1994). "Intravenous self-administration studies with l-deprenyl (selegiline) in monkeys". Clinical Pharmacology & Therapeutics 56 (6): 774–780. doi:10.1038/clpt.1994.208. PMID 7995020.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Monday, January 11, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.